Selected as Final General Partner for Early-Stage Small Fund
Myriad Partners to Lead Investment in Startups Outside the Seoul Metropolitan Area
Myriad Partners (formerly Myriad Life Science), a specialized accelerator and strategic advisory firm in the bio and healthcare sector, announced on April 30 that it has been selected as the final general partner (GP) for the startup early-stage small fund category in the '2025 First Regular Investment Program of the Korea Fund of Funds.'
A total of KRW 14.5 billion has been allocated to the early-stage small fund category of the Korea Fund of Funds investment program. Based on this, a sub-fund of more than KRW 28 billion is planned to be created. The main investment targets are startups that have been established for less than three years and have annual sales of less than KRW 2 billion, as well as companies located outside the Seoul metropolitan area. This year, 34 companies applied as general partners, resulting in a high competition rate of 6.8 to 1.
Myriad Partners was recognized for its extensive experience in strategic advisory services such as technology valuation, business development, and IPO support, all centered on the bio and healthcare sector, as well as its experience in venture creation and early-stage investment. In addition, New Paradigm Investment, CN Venture Partners, TAP Angel Partners, and the Gwangju Center for Creative Economy & Innovation-GIST Holdings consortium were also selected as GPs in the same category.
Myriad Partners CEO Sung Sangyong stated, "I believe this is the result of the positive assessment of the investment and nurturing capabilities we have steadily built up over time," and added, "Going forward, we aim to continue serving as a reliable partner for early-stage companies and to contribute, even in a small way, to the creation of an innovative startup ecosystem in the bio and healthcare industry."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
